On March 17, the official website of the Medicines Patent Pool (MPP) announced that it has signed agreements with 35 companies that are allowed to imitate the production of nirmatrelvir, one of the components of Pfizer’s new crown oral drug Paxlovid. There are 5 pharmaceutical companies in China, including Huahai Pharmaceutical (600521), Puluo Pharmaceutical (000739), Fosun Pharmaceutical (600196), Jiuzhou Pharmaceutical (603456), Shanghai Desano, among which Jiuzhou Pharmaceutical The industry only produces APIs, while others can produce APIs and preparations at the same time.
Market rumors of Pfizer’s new crown oral drug generic license have been confirmed.
On March 17, the official website of the Medicines Patent Pool (MPP) announced that it has signed agreements with 35 companies that are allowed to imitate the production of nirmatrelvir, one of the components of Pfizer’s new crown oral drug Paxlovid.
Judging from the map published on the official website, the countries involved in the agreement are distributed in 12 countries around the world, of which 6 companies will focus on the production of APIs, 9 companies will produce pharmaceuticals, and the remaining 20 companies will have both. There are 5 pharmaceutical companies in China, including Huahai Pharmaceutical (600521), Puluo Pharmaceutical (000739), Fosun Pharmaceutical (600196), Jiuzhou Pharmaceutical (603456), Shanghai Desano, among which Jiuzhou Pharmaceutical The industry only produces APIs, while others can produce APIs and preparations at the same time.
Notably, the agreement will help expand access to Pfizer’s Covid-19 oral medicines in 95 low- and middle-income countries, which represent about 53% of the world‘s population, but not China.
Earlier on March 17, the market spread the above news, and the above listed companies once rose by the daily limit. Previously, there were market rumors that Puluo Pharmaceuticals could only produce APIs. Judging from the newly released map, Puluo Pharmaceutical can produce APIs as well as preparations.
It is worth noting that a Ukrainian company is also on the list of 35 companies. The MPP said it could not sign because of the current conflict, but the license could still be used.
According to the official website, the Drug Patent Pool Organization is a public health organization supported by the United Nations, dedicated to increasing access to life-saving medicines and promoting drug development for low- and middle-income countries.
On January 20, local time, the Medicines Patent Pool (MPP) announced through its official website that it has signed agreements with 27 pharmaceutical companies to allow them to produce and supply Merck’s oral anti-new coronavirus drug Molnupiravir to 105 low- and middle-income countries or regions around the world. To promote affordability and accessibility of the drug globally. Five Chinese pharmaceutical companies, including Fosun Pharma, Borui Pharmaceutical, Shijiazhuang Longze Pharmaceutical, Shanghai Desano, and Langhua Pharmaceutical, are among them. The first four are licensed to produce both APIs and finished drugs. Production of APIs.
That is to say, two pharmaceutical companies, Fosun Pharma and Shanghai Desano, have obtained the rights to prevent and control the production of two oral medicines from Pfizer and Merck.
Pfizer’s Paxlovid, a combination therapy of PF-07321332 and ritonavir, has previously obtained conditional marketing approval in China. Merck’s Molnupiravir is an oral nucleoside drug under development that has not yet been approved in China.
Source of this article: The Paper, the original title “Official Announcement! 5 Chinese pharmaceutical companies have obtained the license for free generic production of Pfizer’s new crown oral drugs”
Risk Warning and Disclaimer
Market risk, the investment need to be cautious. This article does not constitute personal investment advice and does not take into account the particular investment objectives, financial situation or needs of individual users. Users should consider whether any opinions, views or conclusions contained herein are appropriate to their particular circumstances. Invest accordingly at your own risk.